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Abstract
Background: Limited data are available assessing vancomycin concentrations in obese critically ill patients.
Currently, there are no studies evaluating dosing requirements in this population who receive vancomycin
administered as a continuous infusion (CI). The aim of this study was to assess whether there was a difference in
the weight-based maintenance dose required to reach a therapeutic vancomycin concentration at 24 hours when
given as a CI in obese versus non-obese critically ill patients.
Methods: A retrospective cohort study of adult obese patients admitted to the SICU between 2013 and 2015
receiving a vancomycin CI (CIV), and with 24-hour serum measurements were included. Obese patients (body mass
index (BMI) ≥35 kg/m2) were matched with non-obese patients (BMI <30 kg/m2) based on renal function, age and
acute physiology and chronic health evaluation (APACHE)-II score at admission. All patients in this study received a
loading dose of 25 mg/kg then a maintenance dose based on renal function according to the protocol. The study
was approved by the Institutional Review Board. The primary outcome was the weight-based total daily maintenance
dose required to achieve a vancomycin level of 20 mg/L. The secondary endpoints included the achievement of a
therapeutic level at 24 hours.
Results: Twenty-six matched pairs of patients met the inclusion criteria. Of these, 17 pairs had preserved renal function
and 9 pairs required continuous venovenous hemofiltration. Mean BMI was 40.9 kg/m2 in obese and 24.8 kg/m2 in
non-obese patients. To achieve a vancomycin concentration of 20 mg/L, the weight-based daily maintenance
dose in obese patients was 25.6 mg/kg versus 43.8 mg/kg in non-obese patients (p <0.01). Therapeutic
24-hour levels were achieved in 24/26 obese versus 23/26 no-obese patients (p = 0.63). Mean 24-hour vancomycin
level was 20.3 ± 3.81 mcg/ml in obese compared to 20.03 ± 3.79 mcg/ml in non-obese patients (p = 0.77). Mean daily
maintenance doses required to achieve a level of 20 mcg/ml were 2961 ± 1670 mg in obese compared to
3189 ± 1600.69 mg in non-obese (p = 0.61).
Conclusions: The results of our study suggest that critically ill obese patients treated with CIV required a significantly
lower maintenance dose per unit of body weight than non-obese patients to achieve the same target level.
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Background
The prevalence of obesity has more than doubled world-
wide since 1980 and it is estimated that 60 % of the
world’s population will be classified as overweight or
obese by the year 2030 [1]. Given this trend, it is
important to characterize the effect of obesity on drug
disposition. Critically ill patients are at risk of alterations
to pharmacokinetics due to having a larger volume of
distribution and alteration in protein binding [2]. Several
physiologic changes in obesity affect antimicrobial
pharmacokinetics. For example, the volume of distribu-
tion in obese patients is greater due to increased lean
body mass and adipose tissue [3]. Drug clearance may* Correspondence: hlin13@partners.org1Department of Pharmacy, Massachusetts General Hospital, 55 Fruit Street,
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also be further enhanced due to increased kidney mass
and filtration [4].
Optimizing antibiotic dosing is a priority in critically
ill patients because inadequate systemic concentrations
may lead to treatment failure and development of anti-
microbial resistance [5]. It is imperative that the initial
dosing regimens provide adequate pharmacodynamic ex-
posure for the most likely pathogen. Vancomycin is the
most common first-line option for treating methicillin-
resistant Staphylococcus aureus or other resistant Gram-
positive bacteria, such as coagulase-negative staphylo-
cocci and ampicillin-resistant enterococci in severe
healthcare-associated infections.
Despite an increasing number of obese patients world-
wide, there is little information on how to optimally dose
vancomycin in these patients. Few studies have evaluated
vancomycin concentrations in obese critically ill pa-
tients, and studies are limited by small patient groups
and utilization of standard intermittent vancomycin dos-
ing [4, 6–10]. Currently, there are no studies evaluating
dosing requirements in this population when receiving
vancomycin continuous infusions (CIV). The aim of this
study was to determine the weight-based dosing require-
ment of CIV necessary to reach the 24-hour target con-
centration in obese versus non-obese critically ill patients.
Methods
We reviewed all adult patients (≥18 years old) who re-
ceived CIV, either as monotherapy or combined with
other antibiotics, in our multidisciplinary surgical ICU
between January 2013 and January 2015. Patients were
identified using the pharmacy informatics system. We
included all adult patients who had a body mass index
(BMI) ≥35 kg/m2, and had measurement of serum
vancomycin concentrations 24 hours after treatment. Pa-
tients who had previously received vancomycin within
48 hours prior to the start of the continuous infusion
(CI) were excluded. The protocol was approved by the
Partners Institutional Review Board, which waived the
need for informed consent because of the retrospective
nature of the study.
Demographic data (age, sex, total body weight (TBW),
ideal body weight (IBW), adjusted body weight (ABW),
height, BMI, creatinine clearance upon vancomycin initi-
ation (CrCL), severity of illness score (acute physiology
and chronic health evaluation (APACHE) II) calculated
at the time of ICU admission, and laboratory parameters
were retrospectively collected for each patient in the
study. ABW was calculated as follows:
ABW ¼ 0:4 TBW – IBWð Þ þ IBW:
TBW was estimated and measured by the nurse using
the patient’s bed scale on the day of vancomycin therapy.
Other gathered data included use of continuous venove-
nous hemofiltration (CVVH), CVVH hemofiltration rate,
use of vasopressors or mechanical ventilation, vanco-
mycin dose, and serum vancomycin concentration.
Nephrotoxicity was defined as an increase in serum cre-
atinine (SCr) by 0.5 mg/dL or at least a 50 % increase
from baseline over two consecutive SCr values for pa-
tients not requiring CVVH.
CI vancomycin clearance (CLvanc) was calculated
using the following equation:
Dose mg=hrð Þ
Serum concentration mg=Lð Þ ¼ CLvanc L=hrð Þ
Area under the concentration curve 24 hr (AUC24)
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The 24-hour urine creatinine clearance (CrCL) was










   Time of urine collection; minutesð Þ
All CVVH treatments applied the CAR-505 filter with
a polyethersulfone membrane with a 1.6 m2 membrane
surface area in conjunction with the NxStage System
One dialysis machine. Vancomycin concentration ana-
lysis utilized a Syva Emit 2000 vancomycin assay
(Siemens Healthcare Diagnostics, Inc. Newark, DE,
USA). The assay has an analytical range between 5.0 and
50.0 mcg/ml, and the between-run coefficient of vari-
ation was <10 % throughout the analytical range.
Vancomycin treatment and measurements
In our surgical ICU, the use of CIV is at the discretion
of the treating ICU physician and at a loading dose of
25–30 mg/kg, followed by maintenance doses adjusted
based on CrCL or CVVH. Calculated CrCL was esti-
mated using the Cockcroft-Gault (CG) equation using
ABW. To account for a falsely elevated CrCL estimate in
patients >65 years of age in whom low SCr values may
indicate reduced muscle mass, SCr values <0.8 mg/dL
were adjusted up to 0.8 mg/dL. CG CrCL was used in
the dosing nomogram because 24-hour urine creatinine
cannot provide immediate results and rapid administra-
tion of antibiotic is often essential. Of note, 24-hour
urine creatinine is not performed daily in the study cen-
ter, instead it is collected on the first day of CIV therapy.
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The daily maintenance dose starts at 2000 mg for CG
CrCL of 60 ml/minute; increases in CG CrCL of 10 ml/
minute requires an increase in maintenance dose of
250 mg vancomycin. The maximum maintenance dose is
started at 4250 mg. For patients who receive concomitant
CVVH, the initial vancomycin dose is 1500 mg daily.
Doses were not changed during the first 24 hours of
therapy; afterwards, the daily regimen was adapted using
a specific approach: if serum vancomycin concentration
was <15 mg/L, an additional dose of 500 to 1000 mg
was given as a bolus followed by an increased total daily
dose proportional to the goal serum concentration. If the
concentration was >25 mg/L, the CIV was discontinued
for 4 to 6 hours and resumed with the daily dose reduced
proportionally. Serum vancomycin concentrations were
determined every 24 hours until two serum concentra-
tions were within target range (15–25 mg/L). If CVVH
was stopped due to a clotted circuit, the CIV was stopped
and the infusion resumes once CVVH was restarted.
Matched controls
Using an institutional database of all ICU patients who
received CIV during the same period, obese ICU pa-
tients (BMI >35 kg/m2) were matched with non-obese
ICU patients (BMI <30 kg/m2) according to three cri-
teria: (1) renal function (either the same 24-hour urine
CrCL with a range of eligibility for matching of 25 ml/
minute, or if on CVVH, the same CVVH intensity with
a range of eligibility for matching of 10 ml/kg/minute);
(2) age (range of eligibility for matching of 15 years); and
(3) APACHE II score at admission (range of eligibility
for matching of 10).
Endpoints
The primary outcome was the weight-based daily main-
tenance dose requirement to achieve vancomycin con-
centration of 20 mg/L at 24 hours. Secondary outcomes
were achievement of a therapeutic level by 24 hours,
CLvanc/IBW, CLvanc/ABW, CLvanc/TBW, and AUC24.
Therapeutic levels were defined as a range of 15 to
25 mg/L to achieve an adequate AUC [11, 12].
Statistical analysis
Distributions of quantitative outcomes were summarized
by the mean with standard deviation and were compared
using the Mann-Whitney U test. Categorical outcomes
were summarized by counts and proportions and
compared using the Chi-square test (or the Fisher’s
exact test as appropriate). Linear regression was used
to identify the correlation between CLvanc and CrCL.
All analyses were performed using STATA Data Analysis
and Statistical Software (version 13; StatCorp LP, College
Station, TX, USA). A p value <0.05 was considered statisti-
cally significant.
Results
Twenty-six matched pairs of patients met the inclu-
sion criteria. Of these, 17 pairs of patients had pre-
served renal function and 9 pairs required CVVH.
Baseline values of ABW, TBW, and percent over IBW
and BMI were significantly different (Table 1). Mean
BMI was 41 kg/m2 in obese and 24.9 kg/m2 in non-
obese patients. In patients with preserved renal func-
tion (n = 34), mean 24-hour urine CrCL was 166 ml/
minute in obese patients versus 168 ml/minute in
non-obese patients. In patients (n = 18) receiving
CVVH, mean hemofiltration rates were 21.3 ml/kg/h
in obese patients versus 21.9 ml/kg/h in non-obese




patients (n = 26)
P
value
Age, years 54.2 (16.8) 55.4 (16.0) 0.781
Male, n 18 21 0.337
TBW, kg 117 (23.3) 75.2 (13.3) <0.001
ABW, kg 87.7 (13.7) 71.0 (11.1) <0.001
IBW, kg 67.9 (13.1) 68.5 (10.5) 0.88
Height, in 67.6 (4.63) 68.5 (3.38) 0.393
Over IBW, % 1.77 (0.43) 1.1 (0.112) <0.001
BMI, kg/m2 41.0 (8.12) 24.9 (3.16) <0.001
APACHE II 20.3 (9.24) 18.7 (8.46) 0.524
Hospital mortality, n 5 4 0.714
Mechanical ventilation, n 24 26 0.149
Use of vasopressors, n 15 20 0.139
CVVH, n 9 9 1
Urine creatinine clearance
(ml/min), n = 17
166 (62.7) 168.1 (59.1) 0.92
CVVH flow rate, ml/kg/h 21.3 (7.09) 21.9 (6.47) 0.86
Duration of vancomycin, days 6.88 (3.02) 6.5 (3.06) 0.415
Time from ICU admission to
vancomycin initiation, days















































Results presented as mean (SD) unless stated otherwise. CVVH continuous
venovenous hemofiltration, TBW total body weight, ABW adjust body
weight, IBW ideal body weight, BMI body mass index, APACHE Acute
Physiology and Chronic Health Evaluation, SSTI skin soft tissue infection,
MRSA methicillin-resistant Staphylococcus aureus, MSSA, methicillin-sensitive
Staphylococcus aureus
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patients. No patients in either group with preserved
renal function developed nephrotoxicity during vanco-
mycin treatment.
Endpoints
For the primary endpoint, the weight-based daily main-
tenance dose required to achieve a therapeutic 24-hour
serum concentration in obese patients was 24.8 mg/kg
versus 41.9 mg/kg in non-obese patients (p < 0.001)
(Table 2). There was no difference between groups in
the mean 24-hour vancomycin serum concentration,
mean daily maintenance doses, AUC24, or achievement
of therapeutic concentration within 24 hours. Mean
loading doses were 24.8 mg/kg versus 25.6 mg/kg in
obese and non-obese patients, respectively, p = 0.135.
In the subgroup of 18 patients who received CVVH,
there was no difference in the CLvanc/ABW or CLvanc/
IBW (Table 3). CLvanc/TBW was significantly lower in
obese than non-obese patients, p = 0.04. There was no
correlation between CLvanc and TBW, IBW or ABW.
There was strong positive correlation between CLvanc
(L/h) and CVVH flow rate in obese patients (r2 = 0.93,
p < 0.001) but poor correlation in non-obese patients
(r2 = 0.2, p = 0.226).
In the subgroup of 34 patients with preserved renal
function, obese patients had significantly lower CLvanc/
CrCL than non-obese patients, p = 0.04 (Table 4). Mean
CLvanc in the obese group was 0.06 L/h per kg TBW,
whereas non-obese patients had a CL of 0.12 L/h per kg
TBW. There were no significant differences between
obese and non-obese patients in CLvanc and CLvanc
adjusted for IBW. There was no correlation between
CLvanc and TBW in any patients as shown in Fig. 1a
and b. There was good correlation between vancomycin
CL and CrCL in obese patients (r2 = 0.87 p < 0.001) and
non-obese patients (r2 = 0.661, p < 0.001) as shown in
Fig. 2a and b.






Loading dose, mg 2894 (525) 1923 (345) <0.001
Loading dose, mg/kg 24.8 (2.05) 25.6 (1.66) 0.135
Maintenance dose, mg 2885 (1450) 3039 (1313) 0.69
Maintenance dose, mg/kg 24.8 (12.7) 41.9 (20) <0.001
24 hour serum concentration,
mg/L
20.3 (3.81) 20.0 (3.79) 0.777
CLvanc, L/h 6.16 (3.47) 6.64 (3.33) 0.617
Dose needed to achieve
concentration of 20 mg/L, mg
2961 (1670) 3189 (1601) 0.617
Dose per ABW needed to achieve
concentration of 20 mg/L, mg/kg
25.57 (14.8) 43.8 (23.5) <0.01
AUC24 488. (91.5) 480.9 (91.04) 0.777
Achievement of therapeutic
concentration at 24 hours, n
24 23 0.638
Results are presented as mean (SD) or number. CLvanc continuous infusion
vancomycin clearance, ABW adjusted body weight, AUC24 area under the
concentration curve 24 h




patients (n = 9)
P value
Goal concentration, 24 h, n 9 9 1
Serum concentration, 24 h, mg/L 19.8 (3.05) 21.6 (3.02) 0.155
Dose needed to achieve
concentration of 20 mg/L, mg
1426 (418) 1383 (282) 0.802
Dose needed to achieve
concentration of 20 mg/L, mg/kg
13.8 (5.09) 19.9 (6.7) 0.004
Loading dose, mg 2722 (441) 1833 (280) <0.001
Loading dose, mg/kg 25.3 (0.774) 25.4 (1.49) 0.847
Maintenance dose, mg 1389 (397) 1500 (375) 0.550
Maintenance dose, mg/kg 13.3 (4.73) 21.7 (8.33) 0.01
AUC24 474 (73.2) 517 (48.6) 0.15
CLvanc, L/h 2.97 (0.87) 2.88 (0.60) 0.802
CLvanc/ABW, L/h/kg 0.04 (0.01) 0.04 (0.01) 0.34
CLvanc/IBW, L/h/kg 0.02 (0.02) 0.05 (0.01) 0.879
CLvanc/TBW, L/h/kg 0.03 (0.01) 0.04 (0.01) 0.044
Results are presented as mean (SD) unless stated otherwise. CVVH continuous
venovenous hemofiltration, AUC24 area under the concentration curve 24 h,
CLvanc continuous infusion vancomycin cl, ABW adjusted body weight, IBW
ideal body weight, TBW total body weight





patients (n = 17)
P value
Goal concentration, 24 h, n 15 14 0.628
Serum concentration, 24 h, mg/L 20.6 (4.21) 19.6 (4.41) 0.494
Dose needed to achieve
concentration of 20 mg/L, mg
3774 (1498) 4141 (1087) 0.420
Dose needed to achieve
concentration of 20 mg/L, mg/kg
31.8 (14.5) 56.9 (17.9) <0.001
Loading dose, mg 2985 (555) 1941 (370) <0.001
Loading dose, mg/kg 24.6 (2.47) 25.9 (1.88) 0.09
Maintenance dose, mg 3676 (1131) 3882 (674) 0.523
Maintenance dose, mg/kg 30.8 (11.3) 53.4 (13.7) <0.001
AUC24 496 (101) 471 (106) 0.494
CLvanc, L/h 7.86 (3.11) 8.62 (2.26) 0.420
CLvanc/CrCL 0.79 (0.11) 0.91 (0.21) 0.049
CLvanc/ABW, L/h/kg 0.09 (0.04) 0.12 (0.04) 0.0074
CLvanc/IBW, L/h/kg 0.12 (0.05) 0.12 (0.04) 0.404
CLvanc/TBW, L/h/kg 0.06 (0.03) 0.12 (0.04) 0.0001
Results are presented as mean (SD) unless stated otherwise. AUC24 area under
the concentration curve 24 h, CLvanc continuous infusion vancomycin
clearance, CrCL creatinine clearance, ABW adjusted body weight, IBW ideal
body weight, TBW total body weight
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Discussion
To our knowledge, this is the first study to evaluate the
dosing requirements of CIV in obese critically ill pa-
tients compared to a non-obese cohort. Our study has
several key findings. First, the daily weight-based dose of
CIV is significantly lower for obese patients than non-
obese patients, thereby, reducing total drug exposure
and potentially lowering their risk of kidney injury.
Second, vancomycin clearance is similar in obese and
non-obese patients and is poorly correlated with TBW.
Finally, our results highlight that our CIV dosing proto-
col reliably achieved therapeutic concentrations in both
obese and non-obese critically ill patients.
Continuous vancomycin infusions reduce total daily drug
exposure in obese patients
CIV has been proposed as an alternative approach to
optimize drug concentrations and efficacy in various
critically ill patient populations. Although CI has not
been proven to be superior to intermittent infusion for
clinical effectiveness, CI enhances the probability of
achieving optimal drug exposure and lessens the renal
toxicity potential associated with more aggressive dosing
[13]. For example, Hanrahan et al. demonstrated that pa-
tients who received intermittent vancomycin infusions
had 8.2 times greater odds of developing nephrotoxicity
compared to CIV [14]. The risk of nephrotoxicity is fur-
ther amplified in obese patients who traditionally receive
significantly higher doses.
Vancomycin clearance in obese patients is similar in
non-obese patients and is not significantly associated
with TBW
Previous studies have identified greater CLvanc in obese
patients with normal serum creatinine [8, 9, 15]. As
obese patients have a larger volume of distribution (Vd),
they may have a higher CrCL and CLvanc. It has also
been theorized that obese patients have a larger Vd due
to greater quantity and size of nephrons and increased
blood flow to the kidney [16, 17]. Bauer et al. demon-
strated that the extent of CLvanc increased significantly
more than the increase in Vd in morbidly obese patients,
suggesting a much shorter half-life [8]. However, in our
study, we found no difference in CLvanc between obese
and non-obese patients with preserved renal function.
After adjusting CLvanc for various body weights, we
observed no difference in CLvanc/IBW. This may imply
that the potential increase in Vd in obese patients does
not change proportionally to CLvanc.
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Fig. 1 a Correlation of continuous infusion vancomycin clearance
(CLvanc) and total body weight in obese patients (n = 26).
b Correlation of CLvanc and total body weight in non-obese
patients (n = 26)











































Fig. 2 a Correlation between continuous infusion vancomycin
clearance (CLvanc) and creatinine clearance (CrCL) in obese patients
with preserved renal function (n = 17). b Correlation between
CLvanc and CrCL in non-obese patients with preserved renal
function (n = 17)
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Consensus guidelines recommend using TBW to guide
vancomycin dosing because data indicate that TBW pre-
dicts CLvanc in obese individuals [18]. Contrary to the
previous findings we did not identify correlation between
CLvanc and TBW in either group [7, 8]. In our study the
only variables statistically significantly associated with
CLvanc were urine CrCL and CVVH hemofiltration rate.
Both obese and non-obese patients with the same urine
CrCL or CVVH hemofiltration rate required the same
total daily vancomycin as a CIV to achieve the target
concentration. Differences in our study population are a
plausible explanation for these results: in previous stud-
ies, patients had TBW at least 90 % over the IBW and
had higher BMI compared to the patients in our study.
The consequences of varying Vd in obesity can affect
CLvanc and its relationship with TBW. Second, our
study population represents critically ill patients who
may have greater non-renal clearance compared to a
non-ICU population. Therefore, when utilizing CIV in
critically obese patients, our data suggest that clinicians
should rely on 24-hour measured CrCl or the CVVH
hemofiltration rate rather than TBW to assess CLvanc.
Additional studies are needed to confirm these findings.
The strengths of our study include a well-matched
cohort of obese and non-obese critically ill patients, use
of a standardized CIV protocol, and incorporation of 24-
hour measured CrCl to estimate renal clearance of
vancomycin. Cockcroft-Gault CrCL (CG CrCL) is one of
the most commonly used methods for estimating renal
function in the ICU. Most pharmacokinetics studies in
critically ill patients rely on CG CrCL to estimate drug
clearance and adjust drug dosages. However, the use of
CG CrCL to estimate CrCL raises several concerns as it
has been repeatedly shown to be inaccurate in the crit-
ical care setting, in particular, among patients with aug-
mented renal clearance [19]. Only measured urine CrCL
should be used to accurately guide drug dosing [20].
Our study is limited by its retrospective nature, as the
data are subject to inherent biases and small sample size.
Our patient population was representative of younger,
obese critically ill surgical patients with high illness
severity scores and mortality rates. Although our obese
cohort was well-matched with a non-obese cohort, the
subgroup of patients with preserved renal function had
high mean creatinine clearance. Therefore, our findings
may not be applicable to older, non-surgical ICU pa-
tients with impaired renal function. Additionally, the
precision of the measurement of TBW in the study pa-
tients cannot be confirmed. Many confounders, such as
the presence of a sheet, pillow, blanket and equipment
on the patient’s bed can falsely affect weight obtained
from the bed scale and may not accurately reflect true
TBW. Our study results rely on the precision of mea-
sured urine CrCL and it is not possible to rule out the
potential for incomplete urine collection. We did not
record data on clinical and microbiological response to
vancomycin. Only half of our studied patients had a
documented infection with Gram-positive bacteria;
therefore, determining whether optimizing antibiotic
concentrations with CIV leads to improved outcomes
requires further study. Last, we did not assess the ad-
equacy of our loading dose and the effects on vanco-
mycin concentrations at 24 hours.
Conclusion
Utilization of CIV in obese patients consistently achieves
target therapeutic serum concentrations and reduces the
total weight-based daily exposure of vancomycin com-
pared to non-obese patients. CIV clearance is similar in
obese and non-obese patients and does not increase pro-
portionally to TBW.
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